DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-01-09 DOI:10.1002/cam4.70528

Romane Muletier, Céline Bourgne, Laurent Guy, Aurore Dougé

{"title":"DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications","authors":"Romane Muletier, Céline Bourgne, Laurent Guy, Aurore Dougé","doi":"10.1002/cam4.70528","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Prostate cancer is a common cancer with a variable prognosis. Its management is currently guided by histological and biological markers such as the Gleason score and PSA. Developments in molecular biology are now making it possible to identify new targets for better classification of prostate cancer. Among emerging biomarker, DNA methylation, an epigenetic process, is increasingly being studied in carcinogenesis. Techniques for analyzing DNA methylation are constantly improving, and digital PCR now allows absolute methylation quantification with high sensitivity. These techniques can be performed on circulating tumor DNA.</p>\n </section>\n \n <section>\n \n <h3> Materials & Methods</h3>\n \n <p>We conducted a literature review of scientific articles addressing the topic of DNA methylation in prostate cancer.</p>\n </section>\n \n <section>\n \n <h3> Results & discussion</h3>\n \n <p>This review summarizes the different genes whose methylation is involved in carcinogenesis and their clinical implications, both diagnostic and prognostic. Methylation monitoring could also be useful for the prediction of treatment response. However, most studies are retrospective, and prospective studies are needed to validate these data.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 1","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714017/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70528","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Prostate cancer is a common cancer with a variable prognosis. Its management is currently guided by histological and biological markers such as the Gleason score and PSA. Developments in molecular biology are now making it possible to identify new targets for better classification of prostate cancer. Among emerging biomarker, DNA methylation, an epigenetic process, is increasingly being studied in carcinogenesis. Techniques for analyzing DNA methylation are constantly improving, and digital PCR now allows absolute methylation quantification with high sensitivity. These techniques can be performed on circulating tumor DNA.

Materials & Methods

We conducted a literature review of scientific articles addressing the topic of DNA methylation in prostate cancer.

Results & discussion

This review summarizes the different genes whose methylation is involved in carcinogenesis and their clinical implications, both diagnostic and prognostic. Methylation monitoring could also be useful for the prediction of treatment response. However, most studies are retrospective, and prospective studies are needed to validate these data.

查看原文本刊更多论文

前列腺癌中的DNA甲基化：临床意义和潜在应用。

背景：前列腺癌是一种常见的癌症，预后多变。其管理目前是由组织和生物标志物，如格里森评分和PSA指导。分子生物学的发展使得鉴别前列腺癌分类的新靶点成为可能。在新兴的生物标志物中，DNA甲基化作为一种表观遗传过程，在癌变过程中的研究越来越多。分析DNA甲基化的技术在不断改进，数字PCR现在允许高灵敏度的绝对甲基化定量。这些技术可以在循环肿瘤DNA上进行。材料与方法：我们对有关前列腺癌DNA甲基化的科学文章进行了文献综述。结果与讨论：本文综述了甲基化参与肿瘤发生的不同基因及其在诊断和预后方面的临床意义。甲基化监测也可用于预测治疗反应。然而，大多数研究是回顾性的，需要前瞻性研究来验证这些数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.